secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2026-08-12T11:10:23+00:00
Accession:  0001104659-26-094445
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cypherpunk Q2 net income $39.4M on ZEC gain; FDA aligns on Phase 3 for sirexatamab
--------------------------------------------------------------------------------

- Net income $39.4M ($0.18/diluted) vs net loss $16.6M in Q2 2025, driven by $46.0M unrealized gain on ZEC treasury.
- ZEC treasury 323,394.38 ZEC (avg cost $341.83, ~1.92% of supply); ZEC price rose from $243.35 to $400.09 in Q2.
- FDA aligned on randomized Phase 3 trial (~270 DKK1-high 2L mCRC patients) with dual endpoints ORR/OS; Fast Track granted May 2026.
- DeFianCe Phase 2 published: in DKK1-high above median, sirexatamab improved ORR 38% vs 23.7%, PFS HR 0.61, OS HR 0.42; primary endpoint missed in ITT.
- Cash $7.6M; G&A up to $4.5M from $1.8M; R&D down to $0.2M from $10.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465926094445/0001104659-26-094445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465926094445/tm2620947d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer